Zevra Therapeutics Reports Q3 2026 Revenue of $37.8 Million and Updates MIPLYFFA Regulatory Timeline
Zevra Therapeutics (ZVRA) reported third-quarter revenue of $37.8 million, driven primarily by its product MIPLYFFA, which accounted for $34 million in net U.S. product revenue. The company is currently tracking 13 new prescription enrollments as part of its ongoing launch phase. Looking ahead to regulatory milestones, the company expects a CHMP opinion regarding MIPLYFFA in Q4 2026. Following this, Zevra anticipates filing a supplemental New Drug Application (sNDA) in the first quarter of 2027. These updates provide a roadmap for the product's continued expansion and regulatory progression.
Tickers: $ZVRA
Topics: biotechnology earnings product launch revenue
Read the full article at Seeking Alpha
Part of the story Zevra anticipates filing MIPLYFFA sNDA in Q1 2027 as CHMP opinion remains expected in Q4 (2 articles)